Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?
No Preview Available
Associated Records
File Licence
Editors
Date
2020-08-01
Source Title
Respiratory Physiology and Neurobiology
Journal Title
Journal ISSN
Volume Title
Publisher
ELSEVIER
Melbourne Authors
Affiliation
Florey Department of Neuroscience and Mental Health
Document Type
Journal Article
Subject Code
Citation
Soliz, J., Schneider-Gasser, E. M., Arias-Reyes, C., Aliaga-Raduan, F., Poma-Machicao, L., Zubieta-Calleja, G., Furuya, W. I., Trevizan-Baú, P., Dhingra, R. R. & Dutschmann, M. (2020). Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?. Respiratory Physiology and Neurobiology, 279, https://doi.org/10.1016/j.resp.2020.103476.
Access Status
Access this item via the Open Access location
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
A very recent epidemiological study provides preliminary evidence that living in habitats located at 2500 m above sea level (masl) might protect from the development of severe respiratory symptoms following infection with the novel SARS-CoV-2 virus. This epidemiological finding raises the question of whether physiological mechanisms underlying the acclimatization to high altitude identifies therapeutic targets for the effective treatment of severe acute respiratory syndrome pivotal to the reduction of global mortality during the COVID-19 pandemic. This article compares the symptoms of acute mountain sickness (AMS) with those of SARS-CoV-2 infection and explores overlapping patho-physiological mechanisms of the respiratory system including impaired oxygen transport, pulmonary gas exchange and brainstem circuits controlling respiration. In this context, we also discuss the potential impact of SARS-CoV-2 infection on oxygen sensing in the carotid body. Finally, since erythropoietin (EPO) is an effective prophylactic treatment for AMS, this article reviews the potential benefits of implementing FDA-approved erythropoietin-based (EPO) drug therapies to counteract a variety of acute respiratory and non-respiratory (e.g. excessive inflammation of vascular beds) symptoms of SARS-CoV-2 infection.